| アブストラクト | Bortezomib is a proteasome inhibitor commonly indicated for the treatment of multiple myeloma and non Hodgkin lymphoma. Cardiac adverse drug reactions of this drug are not clearly established. We report case where direct involvement of bortezomib in the occurrence of heart failure is strongly suspected and 22 other cases spontaneously reported to the French Pharmacovigilance System. This report should increase cardiologist awareness about the risk of heart failure related to this drug. Moreover, these cases underline the need for a systematic cardiac screening in patients exposed to bortezomib. |
|---|
| ジャーナル名 | Fundamental & clinical pharmacology |
|---|
| 投稿日 | 2013/6/21 |
|---|
| 投稿者 | Honton, Benjamin; Despas, Fabien; Dumonteil, Nicolas; Rouvellat, Caroline; Roussel, Murielle; Carrie, Didier; Galinier, Michel; Montastruc, Jean Louis; Pathak, Atul |
|---|
| 組織名 | Centre Hospitalier et Universitaire de Toulouse, Service de Cardiologie, F-31432,;Toulouse, France; Institut National de la Sante et de la Recherche Medicale;INSERM, Institut des Maladies Metaboliques et cardiovasculaires I2MC, Universite;de Toulouse, UPS, F-31432, Toulouse, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/23781941/ |
|---|
